ClinicalTrials.gg
CompletedNCT04784910Updated Jul 8, 2024

Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

A Phase 3 interventional study of DWP14012 20mg and Lansoprazole 15 mg in Peptic Ulcer, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
423
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Peptic Ulcer with a site in Korea, Republic of — 4 open to participants now, 5 under way, 3 of them phase 3. Peptic Ulcer · Korea, Republic of.

Enrollment
4th of 16
423 · median 344
Started
2021
with 2 others
Phase 3
7 of 19
2 open now
Registered
14th of 19
by date
Lead sponsor
3 of 19
Daewoong Pharmaceutical Co. LTD.

Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 14th registered.

Peptic Ulcer

146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.

Browse Peptic Ulcer studies →

Open to participants now

4 of the 19 studies in Peptic Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 18 Peptic Ulcer studies recruiting now, 11 (61%) set no upper age limit and 7 (39%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Peptic Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The study aims to demonstrate the preventive effect of DWP14012 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of DWP14012 20 mg.

03

Conditions studied

  • Peptic Ulcer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adults aged ≥ 19 years at the time of
  2. Subjects who are diagnosed with musculoskeletal disease at screening and require continued treatment with NSAIDs for at least 24 weeks
  3. Subjects with at least one of the following risk factors for ulcer development at screening.
  4. Subjects who have no gastric or duodenal mucosal break or have ulcer in the scarring stage based on the EGD result at screening.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with esophagitis, gastroesophageal varix, esophagus, Barrett's esophagus, acute gastrointestinal bleeding and else based on the screening EGD results.
  2. Subjects who have undergone gastroduodenal surgery or total small bowel resection
  3. Subjects with history of disease of hepatic, renal, nervous, pulmonary, endocrine, hemato-oncologic, cardiovascular or urinary system
  4. Subjects who have had a malignant tumor in the last 5 years
  5. Subjects who history of to the IP ingredients, aspirin and NSAIDs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
423 participants (actual)

Study arms

  • Experimental
    DWP14012 20mg

    orally, once daily

    Drug: DWP14012 20mg · Drug: Lansoprazole 15 mg placebo

  • Active comparator
    Lansoprazole 15mg

    orally, once daily

    Drug: Lansoprazole 15 mg · Drug: DWP14012 20mg placebo

Interventions

  • DWP14012 20mg, tablet, orally, once daily for up to 24 weeks

  • Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks

  • DrugDWP14012 20mg placebo

    DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks

  • DrugLansoprazole 15 mg placebo

    Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who develop peptic ulcer by Week 24 as assessed by investigator

    Time frame: at 24 weeks

Secondary outcomes

  1. Proportion of subjects who develop peptic ulcer by Week 12 as assessed by investigator

    Time frame: at 12 weeks

  2. Proportion of subjects with endoscopic gastric or duodenal bleeding** by Week 12 and Week 24

    Time frame: at 12, 24 weeks

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Nov 2023, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 5, 2021
StartActual
May 21, 2021
Primary completionActual
Nov 27, 2023
CompletionActual
Dec 11, 2023
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04784910
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
May 21, 2021
Primary completion
Nov 27, 2023
Completion
Dec 11, 2023
Last update
Jul 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion